ClinicalTrials.gg
TerminatedNCT00503009Updated Dec 28, 2016Results posted

Study Of RV-39 In Patients Who Also Have Asthma

A Phase 4 interventional study of fluticasone propionate/salmeterol and fluticasone propionate in Asthma, sponsored by GlaxoSmithKline. Terminated at 1 site in United States. Open to participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2016-12-28.

Sponsored by GlaxoSmithKline · Phase 4, Interventional, and Treatment

Why this study was terminated
lack of data

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
16
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 147 studies testing fluticasone in Asthma — 1 open to participants now, 4 under way, 2 of them phase 3. Fluticasone · Asthma.

Enrollment
128th of 146
16 · median 100
Started
2007
with 17 others
Phase 4
52 of 147
1 open now
Registered
39th of 147
by date
Lead sponsor
69 of 147
GlaxoSmithKline

Among the 147 studies testing fluticasone in Asthma, this one is the 128th largest by enrollment of the 146 interventional ones that give a count, is one of 18 that started in 2007, is one of 52 in phase 4, and was the 39th registered.

Asthma

4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.

Browse Asthma studies →

Open to participants now

1 of the 147 studies testing fluticasone in Asthma is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About fluticasone

Fluticasone: first FDA approval 1990 (CUTIVATE), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 415 Asthma studies recruiting now, 140 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 145 take children under 18; 105 take healthy volunteers.

This study: 18 Years to 40 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 147 studies testing fluticasone in Asthma, or all of them as a file.
02

Study summary

This study will last up to 9 weeks. Subjects will visit the clinic up to 14 times. Certain clinic visits will include a physical examination, lung function tests, inflammatory cell analysis from nasal secretions and/or sputum, and blood draws. Subjects will inhale an FDA approved virus through their nose which is known to cause the common cold. All study related medications and medical examinations will be provided at no cost to the subject. The drugs used in this study are approved for the age group under study.

03

Conditions studied

  • Asthma

Browse trials for

Keywords

  • Rhinovirus
  • Asthma
04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have asthma for at least 3 months prior to the study.
  • Have been using an allowed pre-study asthma therapy for at least 3 months prior to study.
  • Demonstrate airway hyperresponsiveness following inhalation of bronchoconstrictor.
  • Have a positive allergic status antibody test.

Exclusion criteria

Exclusion Criteria:

  • Have a history of life-threatening asthma.
  • Been hospitalized for asthma within the 24 months prior to the study.
  • Have certain conditions that would make study participation unsafe.
  • The study doctor will evaluate other inclusion and exclusion criteria.
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
16 participants (actual)

Study arms

  • Active comparator
    Arm 1

    Drug: fluticasone propionate/salmeterol

  • Active comparator
    Arm 2

    Drug: fluticasone propionate

  • Placebo comparator
    Arm 3

    Drug: placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline in the Cumulative Lower Respiratory Symptom Score Averaged Over Days 1-4

    The cumulative lower respiratory symptom score consisted of the summary of individual scores assessing cough, shortness of breath, chest discomfort, and wheezing based on the following scale: 0 (not present); 1=mild, clearly present; 2=moderately severe, uncomfortable; 3=severe (best possible score of 12; worst possible score of 0), interfering with sleep or activity. Due to the small sample size, efficacy measures were not analyzed.

    Time frame: Days 1 through 4

Secondary outcomes

  1. Change From Baseline in the Morning Peak Expiratory Flow (PEF) Averaged Over Days 1-4

    PEF measurements were collected via a study-issued electronic peak flow meter. Due to the small sample size, efficacy measures were not analyzed.

    Time frame: Days 1 through 4

  2. Change From Baseline in the Morning Forced Expiratory Volume in One Second (FEV1) Averaged Over Days 1-4

    FEV1 measurements were collected via a study-issued spirometer. Due to the small sample size, efficacy measures were not analyzed.

    Time frame: Days 1 through 4

  3. Change From Baseline in Exhaled Nitric Oxide (eNO) Averaged Over Days 1-4

    eNO was measured using a study-issued monitor. Due to the small sample size, efficacy measures were not analyzed.

    Time frame: Days 1 through 4

07

Results

Posted Aug 17, 2009
Limitations and caveats
Due to the small sample size, efficacy measures were not analyzed.

Participant flow

Participant flow — Overall Study
MilestoneFSC 250/50 mcg BIDFP 250 mcg BIDPlacebo Diskus BID
Started556
Completed433
Not completed123
Withdrew: Protocol violation101
Withdrew: Withdrawal by subject011
Withdrew: Physician decision011

Outcome measures

PrimaryChange From Baseline in the Cumulative Lower Respiratory Symptom Score Averaged Over Days 1-4

The cumulative lower respiratory symptom score consisted of the summary of individual scores assessing cough, shortness of breath, chest discomfort, and wheezing based on the following scale: 0 (not present); 1=mild, clearly present; 2=moderately severe, uncomfortable; 3=severe (best possible score of 12; worst possible score of 0), interfering with sleep or activity. Due to the small sample size, efficacy measures were not analyzed.

Time frame:
Days 1 through 4

No measurements were reported for this outcome.

SecondaryChange From Baseline in the Morning Peak Expiratory Flow (PEF) Averaged Over Days 1-4

PEF measurements were collected via a study-issued electronic peak flow meter. Due to the small sample size, efficacy measures were not analyzed.

Time frame:
Days 1 through 4

No measurements were reported for this outcome.

SecondaryChange From Baseline in the Morning Forced Expiratory Volume in One Second (FEV1) Averaged Over Days 1-4

FEV1 measurements were collected via a study-issued spirometer. Due to the small sample size, efficacy measures were not analyzed.

Time frame:
Days 1 through 4

No measurements were reported for this outcome.

SecondaryChange From Baseline in Exhaled Nitric Oxide (eNO) Averaged Over Days 1-4

eNO was measured using a study-issued monitor. Due to the small sample size, efficacy measures were not analyzed.

Time frame:
Days 1 through 4

No measurements were reported for this outcome.

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
FSC 250/50 mcg BID—0/5 (0%)2/5 (40%)
FP 250 mcg BID—0/5 (0%)1/5 (20%)
Placebo Diskus BID—0/6 (0%)0/6 (0%)
Most frequent other events
Most frequent other events
EventFSC 250/50 mcg BIDFP 250 mcg BIDPlacebo Diskus BID
HeartburnGastrointestinal disorders1/50/50/6
DiarrheaGastrointestinal disorders1/50/50/6
InfluenzaInfections and infestations0/51/50/6

Baseline characteristics

Age, Continuous
Age, Continuous(years)FSC 250/50 mcg BIDFP 250 mcg BIDPlacebo Diskus BIDTotal
Mean20.4 ± 2.0720.0 ± 1.0023.0 ± 5.8321.25 ± 3.8
Gender
Gender(Participants)FSC 250/50 mcg BIDFP 250 mcg BIDPlacebo Diskus BIDTotal
Female0235
Male53311
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)FSC 250/50 mcg BIDFP 250 mcg BIDPlacebo Diskus BIDTotal
White52411
African American/African Heritage0202
American Indian/Alaskan Native/Native Hawaiian/Pac0011
Asian0112
08

Study locations

1 site
  • GSK Investigational Site
    Charlottesville, Virginia 22908, United States
09

References and documents

Individual participant data

Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2007, a primary completion of Jul 2008 and a completion of Jul 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2009, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 17, 2007
First posted
Jul 18, 2007
Start
Oct 2007
Primary completionActual
Jul 2008
CompletionActual
Jul 2008
Results first posted
Aug 17, 2009
Last update
Dec 28, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 28, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00503009
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Jul 18, 2007
Start date
Oct 2007
Primary completion
Jul 2008
Completion
Jul 2008
Results posted
Aug 17, 2009
Last update
Dec 28, 2016

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Fluticasone · Salmeterol Xinafoate

Start the discussion